INTRODUCTION
Influenza A Virus (IAV) has been a continuous global threat to human health for several years with significant mortality. Recently emergence of Influenza A/2009 H1N1 virus has shaken the world and has revealed the poor defense system human has developed to curb this virus. Antivirals are becoming largely ineffective due to the emergence of resistance for these drugs (Calfee and Hayden, 1985) . As a prophylactic measure though inactivated seasonal influenza vaccines are formulated every year, yet these are effective only for a short time period as new strains emerge due to the phenomena of genetic shift and drift, shown by IAV. As a result new formulations of vaccine are needed every season. Therefore, there is an urgent requirement for some novel strategy for prevention and management of influenza. RNAi (RNA interfering) mechanism, induced by small interfering RNA (siRNA), is the post transcriptional gene silencing method, which offers great hope in the field of anti-viral drug discovery.
. siRNA has a potential as therapeutic agent for many viral infections (Coburn and Cullen, 2002 , Kapadia et al., 2003 , Shlomai and Shaul 2003 . SiRNA is about 19-21 nucleotides long dsRNA which initiates the cascade of enzymatic reactions leading to stimulation of RNAi mechanism in living cells.
Its efficiency in silencing any gene depends upon factors like; criteria used to design siRNAs, variations in transfection efficiency, susceptibility of targeted gene and sensitivity of assay etc. Rational designing of siRNA should increase the rate of success as structure of siRNA is the most important determinant of efficacy (Harborth et al., 2003) . Shifting the target sequence of siRNA by only few nucleotides affects the activity (Holen et al., 2002) .
IAV is a member of Orthomyxoviridae family. Being single stranded RNA virus, IAV becomes an approachable target of anti-influenza RNAi. Its genome is divided into eight segments which encode for eleven proteins. Previous studies have shown efficacy of siRNAs targeting various viral genes of IAV with variable efficacy (Ge et al., 2003 (Ge et al., , 2004 Hui et al., 2004; Tompkins et al., 2004) . PB1 is known to be quite conserved among various strains of IAV and encodes for a protein, which is a major part of polymerase complex. 
MATERIALS AND METHODS

Retrieval of sequences
For the purpose of present study, all the sequences of polymerase Basic gene 1 (PB1) of IAV, already present in Influenza Virus Resource of NCBI database (www.ncbi.nlm.nih. gov/genomes/FLU/database) using advanced search, were initially selected. To facilitate the analysis, sequences were shortlisted following the criteria of including one sequence from single country during single year. However, all the strains which were deposited from India in NCBI database after 2009 were included.
Search set in advanced search was defined as sequence type "nucleotide", Type "A", host "human", country/region "Any" and "India" respectively, segment "2(PB1)", subtype "H any" and "N any", sequence length "full length plus" and collection date "from 2009 to 2013" on dated 22.08.2013.
Multiple sequence alignment of PB gene to identify largest ORF (Open reading frame) and largest conserved region
The program MEGA5.05 (clustalw aligner) was used to align these strains. The ORF map of matrix gene of these selected strains identified the largest ORF with the help of DNADynamo software (supplier Blue Tractor Software ltd). The conserved regions of > 30 bp were identified in the largest ORF by clustalw aligner, with mismatches in not more than 5% of strains.
siRNA Designing
Finally using "i score designer" program, list of 2256 pairs of siRNAs targeting the chosen ORF was produced. Thereafter 2 nd generation algorithms [i-Score (Ichihara et al., 2007 ), s-Biopredsi (Huesken et al., 2005 and DSIR (Vert et al., 2006) were taken into account for further screening, based on which the important siRNA selection rules were arranged in three levels of screening. Only those pairs which fulfilled all the criteria of previous level, passed to the next level. 1 st level screen included ≥ 50 % value of 2 nd generation algorithms (i-Score ≥ 50, DSIR ≥ 50, S-Biopredsi ≥ 0.5), basic Tuscl Rules (1 st position of sense strand > 100 nucleotides downstream from start codon, GC% between 30 -56%, 23-nt sequence motif 5'AA(N19)TT, if not present then 5'AA(N21) and 5'NA(N21) {N, any nucleotide}) (Elbashir et al., 2001) , ∆ G ≤ -1.5 (free energy value of the most stable secondary structure of siRNA strand). 2 nd level screen (Reynolds et al., 2004 , Zhou et al., 2005 included following criteria. For sense strand (scoring): nt A at position 19 (score 1), nt A at position 3 (score 1), nt U at position 10 (score 1), Start nt G/C (score 1) and No G at 13 (score 1). For anti sense strand (scoring): nt U at 5' end (score 2), nt A at 5' end (score 1), nt AA at 5' end (score 1) and 1 or 2 U/A between 2 nd -5 th position (score 1). Pairs of siRNAs having score of ≥ 6
were selected for further screening. 3 rd level screen considered secondary structures of both the strands, determined by Mfold program (Zuker 2003) . siRNAs having bonds between nucleotides (< 3 in number) of any type (GC, AU, GU), bond between G and C nucleotides (< 2 in number) and types of secondary structure (circular structure plots) (< 2 in number) passed through this level.
A cross-homology search using NCBI blast (http://blast.ncbi.nlm.nih.gov/Blast.cgi) was made on the selected 19 nt sequence to screen if the selected siRNA bears homology to any human gene, to avoid gene silencing of any human gene, i.e., off-target cleavage. 19-mer siRNA was then converted to 27-mer Dicer substrate RNA duplex to increase the efficiency of siRNA (Integrated Device Technology Corp. http://eu.idtdna.com/ scitools/documents/dicer_substrate_rnai.pdf). At 3' end of the sense strand 6 bases were added corresponding to target mRNA and complementary to these 6 bases were added at 5' end of antisense strand. On the 3' end of the sense strand 2 terminal RNA bases were replaced with DNA bases for ease of processing. To help direct dicing, 2 bases 3'-overhang on one side of the antisense strand was added. Then PO 4 group was added at 5' end of sense strand for better RISC entry.
Efficacy of self designed siRNA in inhibiting IAV replication Cell line and its maintenance
The efficacy of above self designed siRNA to inhibit IAV replication was checked on MDCK (Madin Darby Canine Kidney) cell line. It was maintained in MEM (Gibco by Life technologies) supplemented with 10% heat inactivated Foetal Bovine Serum (FBS) (Gibco by Life technologies), antibiotics (100 U of Penicillin G/ml and 100 μg of Streptomycin/ml) and 3% Glutamine (Himedia).
Viruses and viral load quantification
Two clinical isolates of IAV from our center were used in this study; Influenza A/pdm H1N1 [A/India/LKO2151/2012 (H1N1)] and Influenza A/H3N2 [A/India/LKO864/2011(H3N2)]. These strains were cultured in MDCK cell line and virus titre was determined by standard curve formation by real time PCR (Taqman chemistry) using CDC primers and probes for Matrix gene as per method Ngaosuwankul et al., 2010 (Ngaosuwankul et al., 2010 Ngaosuwankul et al., 2010 (Ngaosuwankul et al., 2010 .
Statistical analysis
Result was analyzed statistically to find out silencing efficiency of siRNA. Mean and Standard deviation of triplicate of critical threshold (CT) values and viral load of each set was determined. Percentage inhibition was calculated by finding . percentage increase in CT of virus after siPB1 treatment in comparison to the CT value of virus without any siRNA treatment (VC). ∆CT1 (difference in CT values of virus treated with siPB1 and virus not treated with any siRNA) was calculated to show the silencing effect of siPB1 on virus in given conditions. It depicted virtual silencing.
∆CT2 (difference in CT values of virus treated with siN and not treated with any siRNA) was deciphered to depict any effect of siN on virus replication (Negative silencing). Effect of siRNA against study targets (Actual silencing) ∆∆CT was calculated after normalizing the effect of siN on virus replication. Paired t test was used to calculate the p values between viral loads of both viruses at different time points after treatment with siPB1 on MDCK cell line (GraphPad Prism 6 version 6.02, GraphPad Software, Inc., California, Corporation). Repeated measure ANOVA test was used to calculate the p value of the inhibition of Influenza A/pdm H1N1 and Influenza A/H3N2 strains replication on MDCK cell line by siPB1. P value < 0.05 was taken as significant.
RESULTS
siRNA Designing
The search for IAV PB1 gene full length sequences available on NCBI database from all over the world gave 5567 results, out of which 147 were selected taking only one from those isolated from same place and same year. Along with these 42 sequences deposited from India were also included in the study. The accession no. of 189 sequences used in the study are mentioned in Table 1 . Table. 1: Accession numbers of Polymerase Basic 1 gene of IAV used to decipher most active siRNA, retrieved from NCBI (Influenza virus resource).
Accession Number of Nonstructural 1 gene of IAV From India
From rest of World   HM241695  CY088672  JQ340007  JF764086  JX262205  JX262206  JF764085  KF280733  KF280669  KF280661  KF280677  KF280685  KF280693  KF280701  KF280709  KF280717  KF280741  KF280749  KF280725  HM241702  HM460507  HQ154078  HQ853589  HQ853591  HM460510  HQ154076  HQ853571  HQ154084  CY088679  CY088686  CY088707  CY088658  CY088665  HM241716  CY088630  CY088637  HM241723  CY088693  CY088700  CY088651  CY088644  HM241709   CY039899  CY083916  CY129916  GU136025  KC781897  CY093261  KC883401  GU367337  CY071384  CY097946  CY073457  CY066829  HM569665  KC881878  HM189318  CY071424  CY063596  CY071141  CY129668  GQ258464  CY055532  CY066517  CY071333  CY088767  CY083751  CY045501  GQ183623  JF816660  CY073180  CY071381  GU592903  CY044145  CY093405  CY129596  CY128473  CY056993  CY129980   CY125781  CY125797  CY120721  CY120753  CY121798  CY065760  CY083549  CY097978  GQ329075  CY129860  CY081492  CY081468  JQ714244  GQ359772  HM241695  JN703380  CY093195  KC488877  JF682627  JX913065  CY069299  CY083030  CY129756  CY093222  CY080270  JQ340007  JX625636  JX625511  CY121758  CY065934  CY093333  CY121066  KC473860  CY098735  CY080572  CY062809  CY062993   KF001508  CY129836  JQ173146  CY121742  GU931815  CY098756  JQ612505  JF764086  JX262205  CY069475  HM567590  CY041966  GQ251033  CY069315  HQ853589  GU562464  GQ160813  CY069323  CY129588  CY100818  CY093349  CY073156  CY083094  FN423710  CY129432  CY055269  CY118181  CY090843  CY072676  CY088905  CY092295  CY106574  JQ927305  CY100528  CY089461  AB704484  CY087688   CY093373  CY147625  CY125726  GU136041  HQ664919  CY114507  CY114427  CY065798  JF906181  CY113027  HQ703389  CY040040  CY081059  GU290053  CY071648  CY049889  CY093445  CY041981  CY093421  CY096725  KF014996  JX437802  KF015002  JX309436  CY124506  CY079542  CY079535  CY071632  JN187230  JN187225  CY063001  CY063009  CY129556  CY129892  GQ983546  CY074948 Largest ORF from position 7 to 2280 was recognized and multiple sequence alignment of all strains of IAV lead to the identification of following seven conserved regions (> 30 bp long); 109-168nt position, 193 -257nt position, 281-355nt position, 523-572nt position, 1791-1871nt position, 2175-2207nt position and 2271-2315nt position. The largest ORF was chosen as "target" for siRNA activity. Out of total 2256 pairs of I score designer predicted siRNAs, only 184 passed through 1 st level screen, of which 63 were selected for 2 nd level screen, which were in the abovementioned seven conserved regions. 17 sequences scored ≥ 6 in the 2 nd level screen.
Among those seven could pass through 3 rd level screen and the siRNA finally chosen was the one which was falling in the conserved region with < 5% strains mismatches. The chosen duplex showed < 40 alignment score by NCBI Blast showing least off target effect (similarity with any human gene). The characteristics of chosen siRNA are shown in table 2. Table. 2: Characteristics of siRNA chosen for the study.
Name of Gene PB1
Target sequence 
Transfection Experiment
Transfection experiment demonstrated that transfection with 10nM (final concentration) of siGlo Red resulted in almost 100% transfection efficiency (% of cells transfected) at cell density of 10 5 cells per ml in about 24 hrs which declined to nil in about 96
hrs.
In vitro replication inhibition of IAV strains by designed siRNA Viral load of Influenza A/pdm H1N1 and Influenza A/H3N2 on MDCK cell line increased steadily from the time of inoculation to 72 hpi in siN and non-siRNA-treated cells (V P and V S ). In wells treated with siPB1 and challenged by Influenza A/pdm H1N1 viral load decreased steadily upto 72 hpi (Table 3) . In case of wells challenged by Influenza A/H3N2, viral load decreased at 24 hpi, was minimum at 48 hpi and then again increased at 72 hpi. Inhibition of both strains on MDCK cell line in comparison to VC was statistically significant (p value 0.01; paired t test) (Table 3 ). SiPB1 caused 57% inhibition of Influenza A/pdm H1N1 strain while Influenza A/H3N2 was inhibited 60.6%. Virtual silencing (∆CT1) of siPB1 before normalization was 7.25 for A/pdm H1N1 while actual silencing (∆∆CT) after normalization of negative silencing was 6.99. For Influenza A/H3N2 strain virtual silencing (∆CT1) was 6.82, while actual silencing (∆∆CT) came out to be 6.73 (Table 3) .
DISCUSSION
siRNA is highly homology dependent strategy so in present study we planned to delineate the most conserved region of one of the most conserved gene of IAV; PB1 gene by aligning multiple sequences of human pathogenic IAV submitted in NCBI database (Influenza virus resource) from all over the world. This strategy was adopted to develop a siRNA which may work against more or less all IAV strains. siRNAs targeting PB1 gene have demonstrated effective inhibition of Influenza virus replication (Ge et al., 2004; Zhiqiang et al., 2010; Li et al., 2011) . Since the most conserved region of PB1 gene has been targeted, it was demonstrated in silico that it will inhibit wide range of IAV strains.
To achieve substantial amount of success in siRNA silencing two major steps were considered while designing. First, multiple levels of screening were applied following various stringent criteria of siRNA designing to shortlist the best one from a large pool of putative siRNAs as discussed in methods. Second, newer technology of manufacturing Dicer substrate siRNA was used which is supposed to be highly specific. It is described that 25 -30 base length long RNA duplex has 100 times more potency in comparison to its 21 mer counterpart at the same location (Kim et al., 2005) . Therefore, it has been theorized to provide Dicer (an enzyme required to introduce siRNA into RISC -RNA induced silencing complex) with substrate rather than only a product (19-mer) to improve the efficiency of RNA duplex entry into RISC. siRNA was also looked for having no significant homology to any of human gene as we wanted to avoid cross-silencing of human genes while attempting silencing of viral genes.
Present study showed about 60% inhibition of Influenza A/pdmH1N1 and Influenza A/H3N2 within 72 and 48 hrs of virus inoculation respectively, onto pre-siPB1-transfected MDCK cell line. Li et al., also showed the efficacy of siRNA targeting PB1 in . inhibiting IAV propagated on MDCK cell line (Li et al., 2013) . The novelty of the study is the method of designing of siRNA. When siRNA was targeted against the most conserved region in PB1 gene, it inhibited IAV efficiently. SiPB1 inhibited not only Influenza A/H3N2 efficiently but also Influenza A/pdm H1N1. But the inhibition of Influenza A/H3N2 was more in comparison to Influenza A/pdmH1N1, pointing towards the fact that PB1 gene may be having more important role in Influenza A/H3N2 replication rather than in Influenza A/pdmH1N1 replication.
CONCLUSION
IAV infection is known to have limitation of not to be prevented affectively by vaccine or any therapy due to antigenic shift or drift. These results provide a basis for further development of anti IAV -siRNAs. However, as the viral inhibition was only moderate (about 60%), optimization of in vitro conditions, siRNA designing conditions and target selection criteria need to be further fine tuned. 
